Worldwide Clinical Trials Executive and Leadership Team

Daniel Gizachew, the Chief Executive Officer at Worldwide Clinical Trials, directs the overarching corporate strategy and operational execution for the global contract research organization. Overseeing all business units, Gizachew ensures alignment with the company's mission to provide top-performing preclinical and Phase I-IV clinical development services. This leadership role involves driving growth initiatives and maintaining the company's position as a mid-sized CRO serving the biotechnology and pharmaceutical sectors. Daniel Gizachew's strategic vision guides the expansion of full-service clinical experience, from early phase and bioanalytical sciences through late phase studies and post-approval research. The Chief Executive Officer's focus remains on enhancing operational efficiency and fostering innovation across all therapeutic areas, including Cardiovascular, Metabolic, Neuroscience, Oncology, and Rare Diseases, thereby solidifying Worldwide Clinical Trials' market impact.

Keya Watkins, the President, Oncology at Worldwide Clinical Trials, spearheads the strategic direction and operational oversight for all oncology-related clinical development services. Watkins drives the expansion of the company's oncology portfolio, ensuring the delivery of high-quality preclinical and Phase I-IV clinical trials within this critical therapeutic area. This leadership role involves cultivating key relationships with pharmaceutical and biotechnology partners focused on cancer research and treatment. Keya Watkins' expertise guides the execution of complex studies, from early phase research to late-phase trials and post-approval initiatives. The President, Oncology is instrumental in advancing the company's capabilities to address the unique challenges of oncology drug development, contributing directly to patient outcomes. Watkins' leadership ensures Worldwide Clinical Trials remains at the forefront of oncology clinical research.

Alessandra Vignola, the President, Cardiovascular & Metabolic Business Unit at Worldwide Clinical Trials, directs the strategic growth and operational excellence for the company's cardiovascular and metabolic clinical development services. Vignola leads the execution of preclinical and Phase I-IV clinical trials, focusing on advancing treatments for heart disease and metabolic disorders. This executive position involves fostering strong partnerships with clients in the biotechnology and pharmaceutical industries seeking specialized expertise in these major therapeutic areas. Alessandra Vignola's leadership ensures the seamless delivery of comprehensive clinical experience, from early phase studies through post-approval research and real-world evidence generation. The President, Cardiovascular & Metabolic Business Unit drives innovation and efficiency, contributing significantly to the company's overall mission of accelerating medical breakthroughs. Vignola's strategic oversight strengthens Worldwide Clinical Trials' position in these vital fields.

Lisa Skorets, the Chief of Staff, Gcd at Worldwide Clinical Trials, provides critical operational support and strategic project management across the organization. Skorets facilitates communication and execution between executive leadership and various departments, ensuring seamless integration of company-wide initiatives. This role involves managing key projects that enhance the efficiency of preclinical and Phase I-IV clinical development services. Lisa Skorets' responsibilities include optimizing workflows and driving process improvements that directly support the company's mission in therapeutic areas such as Cardiovascular, Metabolic, Neuroscience, Oncology, and Rare Diseases. The Chief of Staff, Gcd ensures that strategic objectives are translated into actionable plans, contributing significantly to the delivery of high-quality clinical research and real-world evidence. Skorets' leadership ensures operational readiness and supports the company's global reach.

Joy Clark, the Chief People Officer at Worldwide Clinical Trials, architects and executes the human capital strategy for the global contract research organization. Clark oversees all aspects of talent management, employee engagement, and organizational development, ensuring a high-performing workforce that supports the company's mission. This leadership position is crucial for attracting, retaining, and developing the specialized talent required for preclinical and Phase I-IV clinical development services. Joy Clark's strategic direction fosters a culture of collaboration and innovation, essential for success in complex therapeutic areas like Cardiovascular, Metabolic, Neuroscience, Oncology, and Rare Diseases. The Chief People Officer drives initiatives that enhance employee experience and align the workforce with the company's growth objectives. Clark's focus on people development ensures Worldwide Clinical Trials maintains its competitive edge in delivering exceptional clinical research solutions.